 Katherine Griem
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 19 | 2017 | 435 | 2.330 |
Why?
| | Brachytherapy | 10 | 2017 | 68 | 1.630 |
Why?
| | Radiation Injuries | 3 | 2012 | 44 | 1.200 |
Why?
| | Radiotherapy, Conformal | 5 | 2011 | 24 | 1.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 5 | 2017 | 77 | 1.020 |
Why?
| | Skin | 2 | 2012 | 136 | 0.840 |
Why?
| | Mastectomy, Segmental | 8 | 2009 | 36 | 0.750 |
Why?
| | Radiotherapy Dosage | 14 | 2017 | 147 | 0.580 |
Why?
| | Radiotherapy, Adjuvant | 5 | 2017 | 81 | 0.510 |
Why?
| | Radiometry | 4 | 2017 | 47 | 0.500 |
Why?
| | Carcinoma, Ductal, Breast | 4 | 2008 | 36 | 0.480 |
Why?
| | Prone Position | 2 | 2011 | 32 | 0.470 |
Why?
| | Thermal Conductivity | 1 | 2012 | 3 | 0.450 |
Why?
| | Thermography | 1 | 2012 | 13 | 0.450 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2009 | 40 | 0.440 |
Why?
| | Lymph Nodes | 2 | 2011 | 84 | 0.430 |
Why?
| | Breast | 3 | 2010 | 25 | 0.410 |
Why?
| | Genital Neoplasms, Female | 1 | 2010 | 14 | 0.380 |
Why?
| | Combined Modality Therapy | 12 | 2010 | 449 | 0.370 |
Why?
| | Axilla | 2 | 2008 | 15 | 0.370 |
Why?
| | Heart | 2 | 2009 | 119 | 0.370 |
Why?
| | Radiodermatitis | 1 | 2009 | 4 | 0.360 |
Why?
| | Taxoids | 1 | 2009 | 17 | 0.360 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 244 | 0.330 |
Why?
| | Female | 26 | 2012 | 18423 | 0.320 |
Why?
| | Middle Aged | 18 | 2011 | 11219 | 0.250 |
Why?
| | Humans | 32 | 2017 | 32988 | 0.240 |
Why?
| | Posture | 1 | 2003 | 90 | 0.240 |
Why?
| | Head and Neck Neoplasms | 4 | 1997 | 141 | 0.220 |
Why?
| | Carcinoma, Squamous Cell | 4 | 1997 | 207 | 0.210 |
Why?
| | Adult | 17 | 2011 | 9848 | 0.200 |
Why?
| | Feasibility Studies | 3 | 2011 | 282 | 0.190 |
Why?
| | Aged | 15 | 2011 | 10542 | 0.180 |
Why?
| | Intraoperative Care | 2 | 2017 | 57 | 0.180 |
Why?
| | Lymph Node Excision | 2 | 1996 | 36 | 0.180 |
Why?
| | Supine Position | 2 | 2011 | 18 | 0.170 |
Why?
| | Radiography | 4 | 2009 | 717 | 0.160 |
Why?
| | Treatment Failure | 2 | 2008 | 186 | 0.150 |
Why?
| | Mice | 2 | 2012 | 1958 | 0.150 |
Why?
| | Lung | 3 | 2011 | 179 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2013 | 3835 | 0.140 |
Why?
| | Neoplasm Staging | 4 | 2010 | 457 | 0.140 |
Why?
| | Accreditation | 1 | 2013 | 18 | 0.120 |
Why?
| | Radiation Oncology | 1 | 2013 | 19 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 2 | 2006 | 235 | 0.120 |
Why?
| | Mice, Hairless | 1 | 2012 | 3 | 0.110 |
Why?
| | Body Water | 1 | 2012 | 7 | 0.110 |
Why?
| | Tomography | 1 | 2012 | 14 | 0.110 |
Why?
| | Animals | 3 | 2012 | 5371 | 0.110 |
Why?
| | Pilot Projects | 3 | 2012 | 466 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 93 | 0.110 |
Why?
| | Fluorouracil | 5 | 1999 | 88 | 0.110 |
Why?
| | Iridium Radioisotopes | 2 | 2008 | 7 | 0.100 |
Why?
| | Electronics | 2 | 2010 | 18 | 0.100 |
Why?
| | Monte Carlo Method | 2 | 2017 | 56 | 0.100 |
Why?
| | Physicians | 1 | 2013 | 136 | 0.100 |
Why?
| | Logistic Models | 1 | 2012 | 474 | 0.100 |
Why?
| | Clinical Competence | 1 | 2013 | 284 | 0.100 |
Why?
| | Internship and Residency | 1 | 2013 | 209 | 0.100 |
Why?
| | Disease-Free Survival | 3 | 2007 | 228 | 0.090 |
Why?
| | Radioisotope Teletherapy | 1 | 1989 | 1 | 0.090 |
Why?
| | Liposarcoma | 1 | 1989 | 6 | 0.090 |
Why?
| | Contracture | 1 | 2009 | 14 | 0.090 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1989 | 15 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 1997 | 378 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 6 | 1996 | 244 | 0.090 |
Why?
| | Organ Size | 1 | 2009 | 119 | 0.090 |
Why?
| | Cisplatin | 4 | 1997 | 106 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2008 | 101 | 0.090 |
Why?
| | Carcinoma, Lobular | 2 | 2007 | 16 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2010 | 4036 | 0.090 |
Why?
| | Thyroid Neoplasms | 1 | 1989 | 50 | 0.090 |
Why?
| | Rectal Neoplasms | 1 | 1989 | 29 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2009 | 225 | 0.080 |
Why?
| | Follow-Up Studies | 7 | 2010 | 2053 | 0.080 |
Why?
| | Models, Biological | 2 | 2004 | 397 | 0.080 |
Why?
| | Carcinoma in Situ | 1 | 2007 | 11 | 0.080 |
Why?
| | Mastectomy | 1 | 1987 | 34 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2009 | 5249 | 0.070 |
Why?
| | Cell Division | 2 | 1996 | 123 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2007 | 899 | 0.070 |
Why?
| | Electrons | 1 | 2004 | 23 | 0.060 |
Why?
| | Theophylline | 1 | 1983 | 2 | 0.060 |
Why?
| | 1-Methyl-3-isobutylxanthine | 1 | 1983 | 6 | 0.060 |
Why?
| | Radiation-Protective Agents | 1 | 1983 | 4 | 0.060 |
Why?
| | Cyclic AMP | 1 | 1983 | 32 | 0.060 |
Why?
| | Reference Values | 1 | 2003 | 250 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 3 | 1996 | 90 | 0.050 |
Why?
| | S Phase | 2 | 1996 | 12 | 0.050 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 1999 | 32 | 0.050 |
Why?
| | Tongue Neoplasms | 1 | 1999 | 17 | 0.050 |
Why?
| | Ventricular Dysfunction, Left | 1 | 1999 | 55 | 0.040 |
Why?
| | Time Factors | 4 | 1996 | 1873 | 0.040 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 1996 | 23 | 0.040 |
Why?
| | Carcinoma | 1 | 1999 | 77 | 0.040 |
Why?
| | Tamoxifen | 2 | 1996 | 35 | 0.040 |
Why?
| | Biopsy | 2 | 1996 | 277 | 0.040 |
Why?
| | Neoplasm Invasiveness | 2 | 1995 | 92 | 0.040 |
Why?
| | Water | 1 | 2017 | 37 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2007 | 20 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 1996 | 14 | 0.040 |
Why?
| | Cellulitis | 1 | 1996 | 7 | 0.040 |
Why?
| | Paclitaxel | 1 | 1996 | 79 | 0.040 |
Why?
| | Cell Count | 1 | 1996 | 114 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 1997 | 61 | 0.040 |
Why?
| | Cell Cycle | 1 | 1995 | 47 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 1996 | 471 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 1997 | 231 | 0.030 |
Why?
| | Apoptosis | 1 | 1996 | 288 | 0.030 |
Why?
| | Survival Rate | 1 | 1995 | 443 | 0.030 |
Why?
| | Neoplasms, Second Primary | 1 | 1994 | 40 | 0.030 |
Why?
| | Male | 7 | 1999 | 17726 | 0.030 |
Why?
| | Postoperative Care | 2 | 1996 | 140 | 0.030 |
Why?
| | Hodgkin Disease | 1 | 1993 | 32 | 0.030 |
Why?
| | Age Factors | 1 | 1995 | 932 | 0.030 |
Why?
| | Safety | 1 | 2010 | 55 | 0.020 |
Why?
| | Cobalt Radioisotopes | 1 | 1989 | 1 | 0.020 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 1989 | 3 | 0.020 |
Why?
| | Anal Canal | 1 | 1989 | 15 | 0.020 |
Why?
| | Child | 2 | 1993 | 1634 | 0.020 |
Why?
| | Preoperative Care | 1 | 1989 | 148 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1987 | 124 | 0.020 |
Why?
| | Hemibody Irradiation | 1 | 2007 | 4 | 0.020 |
Why?
| | Random Allocation | 1 | 1987 | 162 | 0.020 |
Why?
| | Tumor Burden | 1 | 2007 | 38 | 0.020 |
Why?
| | Survival Analysis | 2 | 1997 | 372 | 0.020 |
Why?
| | United States | 1 | 2013 | 2632 | 0.020 |
Why?
| | Equipment Design | 1 | 2006 | 207 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1987 | 368 | 0.020 |
Why?
| | Cell Line | 2 | 1983 | 354 | 0.020 |
Why?
| | Relative Biological Effectiveness | 1 | 2004 | 6 | 0.020 |
Why?
| | Body Burden | 1 | 2004 | 10 | 0.020 |
Why?
| | Particle Accelerators | 1 | 2004 | 8 | 0.020 |
Why?
| | Scattering, Radiation | 1 | 2004 | 41 | 0.020 |
Why?
| | Models, Statistical | 1 | 2004 | 145 | 0.010 |
Why?
| | Actuarial Analysis | 2 | 1995 | 16 | 0.010 |
Why?
| | Cell Survival | 1 | 1983 | 185 | 0.010 |
Why?
| | Computer Simulation | 1 | 2004 | 248 | 0.010 |
Why?
| | Risk Factors | 1 | 1989 | 2762 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1979 | 17 | 0.010 |
Why?
| | DNA, Viral | 1 | 1979 | 103 | 0.010 |
Why?
| | Heart Diseases | 1 | 1999 | 104 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 1997 | 87 | 0.010 |
Why?
| | Esophagectomy | 1 | 1997 | 26 | 0.010 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 1996 | 15 | 0.010 |
Why?
| | Idoxuridine | 1 | 1995 | 2 | 0.010 |
Why?
| | Mitotic Index | 1 | 1995 | 7 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1995 | 8 | 0.010 |
Why?
| | G2 Phase | 1 | 1995 | 5 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 1995 | 31 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 1996 | 111 | 0.010 |
Why?
| | Recurrence | 1 | 1996 | 400 | 0.010 |
Why?
| | Lymphoma | 1 | 1995 | 62 | 0.010 |
Why?
| | Kinetics | 1 | 1995 | 263 | 0.010 |
Why?
| | Regression Analysis | 1 | 1995 | 326 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1995 | 387 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1996 | 434 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1996 | 1117 | 0.010 |
Why?
| | Adolescent | 1 | 1993 | 2687 | 0.000 |
Why?
| | Callitrichinae | 1 | 1979 | 1 | 0.000 |
Why?
| | DNA, Circular | 1 | 1979 | 1 | 0.000 |
Why?
| | Nucleic Acid Denaturation | 1 | 1979 | 1 | 0.000 |
Why?
| | Nucleic Acid Renaturation | 1 | 1979 | 1 | 0.000 |
Why?
| | DNA Restriction Enzymes | 1 | 1979 | 6 | 0.000 |
Why?
| | Exonucleases | 1 | 1979 | 2 | 0.000 |
Why?
| | Haplorhini | 1 | 1979 | 13 | 0.000 |
Why?
| | Microscopy, Electron | 1 | 1979 | 88 | 0.000 |
Why?
|
|
Griem's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|